Jeffrey M. Conroy

Publications:

• August 23, 2024 Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer
• June 20, 2024 Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer
• June 2, 2024 Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer suggests a mechanism of immune evasion and tumor progression
• June 2, 2024 Novel HLA-Ilo/HLA-IIhi phenotype suggests pattern of immune evasion in triple-negative breast cancer
• June 1, 2024 A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability
• April 30, 2024 Immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer
• March 20, 2024 OX40/OX40 Ligand and its Role in Precision Immune Oncology
• March 19, 2024 The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
• February 5, 2024 Automated Tissue Dissection Solution to Support Comprehensive Genomic and Immune Profiling
• September 23, 2023 PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
• August 8, 2023 T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
• June 12, 2023 LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
• June 6, 2023 Sex-specific effects of body composition on tumor microenvironment in non–small cell lung cancer
• June 6, 2023 The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC)
• May 26, 2023 Association of antifolate response signature status and clinical activity of pemetrexed platinum chemotherapy in non-small cell lung cancer - The Piedmont Study
• May 8, 2023 RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers
• March 21, 2022 Cancer testis antigen burden: pan-cancer distribution and survival implications
• November 23, 2024 Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers
• November 23, 2024 Analytical validation of OmniSeq® INSIGHT whole transcriptome sequencing assay to facilitate precision oncology through tumoronly testing in solid tumors
• November 23, 2024 Analytical validation of OmniSeq® INSIGHT whole exome sequencing assay to facilitate precision oncology through tumor only testing in solid tumors
• November 23, 2024 Validation of automated nucleic acid extraction using Covaris® Gen3 extraction methodology on the Assay-Ready Workstation
• October 30, 2024 Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer - a case series of divergent results from a large reference laboratory
• October 29, 2024 A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
• April 7, 2024 Landscape of HIF-1-alpha expression across 24,186 solid tumors using comprehensive immune profiling
• April 7, 2024 Landscape of TIGIT and PD-L1 co-expression in solid tumors
• February 12, 2024 Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
• February 5, 2024 Fully Automated Extraction of High-Quality Total Nucleic Acids from FFPE Specimens using Covaris truXTRAC® FFPE SMART Solutions & Hamilton Robotics
• February 5, 2024 Implementation of Laboratory Automation to Support Scaling of Cancer Patients Testing using OmniSeq® INSIGHT Molecular Diagnostic Test
• January 30, 2024 LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes
• January 13, 2024 Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity
• December 11, 2023 Findings of clinically significant variants (Tier IA) with comprehensive genomic profiling in a breast cancer patient cohort
• December 11, 2023 Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer
• November 17, 2023 Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response
• November 17, 2023 Genomic stability of prostate cancers with homologous recombination gene alterations
• November 17, 2023 Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy
• November 17, 2023 Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making
• November 17, 2023 LAG-3 expression by RNA next-generation sequencing: Comparison with LAG-3 immunohistochemistry in melanoma
• November 17, 2023 A Consensus-Based Machine Learning Framework to Determine Genetically Inferred Ancestry (GIA) from Comprehensive Genomic Profiling (CGP) Sequencing Results
• November 4, 2023 Distinct immunotherapy immune response phenotypes in non-small cell lung cancer present with unique genomic alteration profiles
• November 3, 2023 Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers
• November 3, 2023 Characterization of gene expression signatures of tumor immunogenicity and cellular proliferation from murine cancer models grown in vitro and in vivo
• November 3, 2023 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
• November 3, 2023 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)
• November 3, 2023 Immune microenvironment of primary versus metastatic melanoma of the brain
• November 3, 2023 Metastatic triple negative breast cancer has distinct tumor immune landscape
• November 1, 2023 Comprehensive Genomic and Immune Profiling of Early-Onset Colorectal Cancer
• September 1, 2022 Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
• March 1, 2022 Checkpoint coexpression landscape in gastroesophageal adenocarcinoma
• January 1, 2018 Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors
• February 14, 2024 Cancer testis antigen burden (CTAB): a novel biomarker of tumor‑associated antigens in lung cancer